Taken together, the increased effect of simultaneous GIPR and GLP-1R agonism relative to GLP-1R monoagonism on AgRP neuron dynamics aligns with mounting evidence for the superior efficacy of combined GIP and GLP-1R activation for the treatment of obesity (25–28), and may represent a partial mechanism for the remarkable weight loss induced by dual incretin agonism. The gene discussed is GIPR; the disease is obesity disorder.